Alnylam Pharmaceuticals, Inc. — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
ALNY
Alnylam Pharmaceuticals, Inc. · Biotechnology
FCF$465mC
Rev+65.2%A
D/E2.76D
P/E78.5xD
PEG0.54A-
73.4Score
$311.45$41.6B
1Y Target$437.50Analyst consensus · 24 analysts
5Y Target$640.54Compound horizon
10Y Target$950.20Long-dated conviction
FCF$465mTTMC
FCF $465m — modest; watch for margin expansion
Rev+65.2%TTM YoYA
Revenue +65.2% — hypergrowth, top decile
D/E2.76D
D/E 2.76 — most levered decile in Healthcare (≈95th pctile)
P/E78.5xD
P/E 78.5 — most expensive decile in Healthcare (≈95th pctile)
PEG0.54A-
PEG 0.54 — strong; Lynch's preferred zone
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 73.4
Quality0.64
Growth1.00
Value0.62
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week low
37% off the 12-month high
vs DCF fair value281% aboveest. fair value ~$82
Quality signals · context only
Gross profitability61% · Agross profit ÷ total assets (Novy-Marx)
ROIC27.0% · Areturn on invested capital — not score-weighted
Why now
Biotechnology · market cap $41.6b. Down 37% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.54 — paying under fair value for the growth rate. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $437.50 (implying +40% upside).
Moat
ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 167% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.76 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trailing P/E 78.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $437.50 (24-analyst consensus) — fundamentals + valuation re-rating. 5 yr $640.54 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $950.20 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · ALNY
Trend
-0.7 over 14 daily scores
From 74.1 (Jun 22) → 73.4 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · ALNY
$
%
%
Shares to buy
6
Position size
$1,869
3.7% of portfolio
Stop price
$233.59
25% below $311.45
$ at risk if stopped
$467.18
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Alnylam Pharmaceuticals, Inc. (ALNY): score, valuation & FAQ
Alnylam Pharmaceuticals, Inc. (ALNY) is a Biotechnology company that scores 73.4 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and PEG (A-), while D/E (D) and P/E (D) rate weaker. On valuation, ALNY sits about 281% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is ALNY a good stock to buy?
Bull Rankings scores ALNY 73.4 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A) and PEG (A-). A score is a quantitative screen of Alnylam Pharmaceuticals, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ALNY score 73.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ALNY earns its highest marks on Rev (A) and PEG (A-), and is held back by D/E (D) and P/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ALNY overvalued or undervalued?
Based on $311.45, ALNY sits about 281% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 78.5x× P/E (graded D). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ALNY?
D/E 2.76 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trailing P/E 78.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.